Gilbert H. Kliman Sells 2,000 Shares of Glaukos Co. (NYSE:GKOS) Stock

Glaukos Co. (NYSE:GKOS) Director Gilbert H. Kliman sold 2,000 shares of the business’s stock in a transaction on Wednesday, December 11th. The shares were sold at an average price of $144.01, for a total transaction of $288,020.00. Following the sale, the director now directly owns 32,336 shares of the company’s stock, valued at $4,656,707.36. This represents a 5.82 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Glaukos Stock Performance

NYSE GKOS traded down $1.50 during trading hours on Friday, reaching $138.82. The company’s stock had a trading volume of 609,996 shares, compared to its average volume of 569,477. Glaukos Co. has a 52 week low of $65.00 and a 52 week high of $147.65. The stock has a market cap of $7.65 billion, a PE ratio of -45.97 and a beta of 1.03. The company has a current ratio of 5.54, a quick ratio of 4.71 and a debt-to-equity ratio of 0.19. The business has a 50-day simple moving average of $136.25 and a 200 day simple moving average of $126.81.

Glaukos (NYSE:GKOS) last released its earnings results on Monday, November 4th. The medical instruments supplier reported ($0.28) EPS for the quarter, beating the consensus estimate of ($0.48) by $0.20. Glaukos had a negative net margin of 42.43% and a negative return on equity of 18.99%. The firm had revenue of $96.70 million for the quarter, compared to analysts’ expectations of $91.50 million. During the same quarter last year, the company earned ($0.50) EPS. Glaukos’s quarterly revenue was up 23.9% on a year-over-year basis. Equities research analysts predict that Glaukos Co. will post -1.89 earnings per share for the current fiscal year.

Institutional Trading of Glaukos

A number of institutional investors have recently bought and sold shares of the company. Exome Asset Management LLC bought a new position in shares of Glaukos in the 3rd quarter valued at approximately $3,369,000. Franklin Resources Inc. grew its stake in shares of Glaukos by 80.1% in the 3rd quarter. Franklin Resources Inc. now owns 15,621 shares of the medical instruments supplier’s stock valued at $2,031,000 after purchasing an additional 6,948 shares during the period. Tidal Investments LLC lifted its holdings in shares of Glaukos by 83.1% during the third quarter. Tidal Investments LLC now owns 14,908 shares of the medical instruments supplier’s stock valued at $1,942,000 after acquiring an additional 6,767 shares during the period. Sanctuary Advisors LLC bought a new stake in Glaukos during the third quarter worth about $258,000. Finally, Teachers Retirement System of The State of Kentucky increased its holdings in Glaukos by 84.3% during the 3rd quarter. Teachers Retirement System of The State of Kentucky now owns 28,470 shares of the medical instruments supplier’s stock valued at $3,709,000 after purchasing an additional 13,019 shares in the last quarter. Institutional investors and hedge funds own 99.04% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have recently weighed in on the company. Stifel Nicolaus increased their price objective on Glaukos from $145.00 to $153.00 and gave the company a “buy” rating in a report on Monday, December 2nd. Truist Financial increased their target price on shares of Glaukos from $145.00 to $152.00 and gave the company a “buy” rating in a research report on Monday, October 14th. Wells Fargo & Company raised their price objective on shares of Glaukos from $145.00 to $153.00 and gave the stock an “overweight” rating in a research report on Wednesday. BTIG Research upped their price target on Glaukos from $140.00 to $149.00 and gave the stock a “buy” rating in a research note on Tuesday, November 26th. Finally, JPMorgan Chase & Co. increased their price target on Glaukos from $130.00 to $145.00 and gave the company an “overweight” rating in a research report on Tuesday, November 5th. One investment analyst has rated the stock with a sell rating, two have given a hold rating, ten have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $143.17.

Glaukos Company Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.